Cardioprotective effects of amlodipine in the ischemic-reperfused heart by Lucchesi, Benedict Robert & Tamura, Yasuo
PART III: PRECLINICAL AND CLINICAL EXPERIENCE WITH AMLODIPINE 
Cardioprotective effects of amlodipine in the 
ischemic-reperfused heart 
Benedict R. Lucchesi, PhD, MD, and Yasuo Tamura, MD, Ann Arbor, Mich. 
From the Department of Pharmacology, University of Michigan Medical 
School. 
Amlodipine is a dihydropyridine calcium entry- 
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blocking agent characterized as having a slow onset 
macology, University of Michigan Medical School, Medical Science Build- and relatively long duration of action with minimal 















0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 
LEFT VENTRICULAR VOLUME (ml) 
Fig. 1. Left ventricular compliance in the cat-isolated heart before and after being subjected to 60 min- 
utes of global ischemia followed by reperfusion for 60 minutes. Pretreatment with amlodipine resulted in 
a preservation of compliance compared with nontreated control hearts (compare middle graph with that 
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Fig. 2. Tissue concentration of calcium ion in the canine heart after 90 minutes of regional ischemia fol- 
lowed by 6 hours of reperfusion. Amlodipine reduced the calcium content in the noninfarcted tissue within 
the risk region. 
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Fig. 3. Infarct size in the canine heart. The left circum- 
flex coronary artery was occluded for 90 minutes followed 
by 6 hours of reperfusion. Infarct size was assessed by the 
triphenyltertazolium staining method. Pretreatment with 
intravenous amlodipine, 150 pg/kg given 15 minutes before 
reperfusion, resulted in a significant decrease in the size of 
the ultimate infarct. Size of the risk regions in the two 
groups of animals did not differ. 
The protective effect of amlodipine was studied in 
isolated, blood-perfused cat hearts made globally is- 
chemic for 60 minutes followed by reperfusion for 60 
minutes. Ischemia-induced alterations of left. ven- 
tricular-developed pressure and compliance were 
monitored. In 11 control and seven amlodipine- 
treated hearts, amlodipine produced significant de- 
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creases in coronary vascular resistance, as assessed by 
changes in perfusion pressure (120 +- 1 to 100 I 4 
mm Hg) and myocardial oxygen consumption 
(6.2 r 0.4 to 4.4 -t 0.4 ml oxygen/min/lOO gm). Am- 
lodipine administered before the onset of global 
ischemia decreased the development of ischemic 
contracture as reflected by a progressive increase in 
resting left ventricular diastolic pressure (Fig. 1). The 
return of contractile function 60 minutes after reper- 
fusion was improved significantly in the amlodipine- 
treated group compared with controls, and there was 
better maintenance of the tissue concentrations of 
Na+, Ca2+, and K+ (Fig. 2). 
A canine model of regional myocardial ischemia 
(90 minutes) followed by 6 hours of reperfusion was 
used to assess the cardioprotective effects of am- 
lodipine, 150 pglkg, administered 15 minutes before 
reperfusion. Infarct size, expressed as a percentage 
of the area at risk, was significantly smaller in the 
amlodipine-treated group (n = 10) compared with 
the control group (II = 10) (34.5% + 3.8% vs 45.9% 
+ 2.8 % , p = 0.027) (Fig. 3). Risk region size did not 
differ between groups, and both groups were com- 
parable with respect to hemodynamic parameters 
of heart rate, blood pressure, rate pressure product, 
and total blood flow in the left circumflex coronary 
artery. 
We conclude that amlodipine reduces myocardial 
ischemic injury by mechanism(s) that may involve a 
reduction in myocardial oxygen demand, as well as by 
positively influencing transmembrane Ca2+ fluxes 
during ischemia and reperfusion. 
